Seed VC · Luxembourg

Droia Ventures

Active

What they invest in

Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients, specializing exclusively in therapeutics for oncology and genetic disease. The firm actively supports companies from creation through clinical proof of concept, focusing on breakthrough therapies with material impact on patient prognosis.

Who they back

DeepTechHealthtechBiotechTherapeutics for oncology and genetic diseases onlySeedSeries ASeries B+

Business models

biotech_therapeutics, deeptech_ip

Customer segments

Researchers, Biotech Companies

Geography

US, Europe, APAC

Recent investments

  • Accent Therapeutics
  • Actio Biosciences
  • Alesta Therapeutics

+ 3 more deals. Score your deck to see the full investment history.

We never publish partner emails directly — score your deck to unlock contacts for the firms ranked as best-fit.

Why this firm matters for fundraising founders

Droia Ventures writes first institutional checks where the founder + early product matter more than traction. The seed market is the most dispersed segment of venture; matching to thesis (sector, stage, geography) is where most cold outreach succeeds or fails. VCboom tracks Droia Ventures alongside 47,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.

At a glance

Based in
Luxembourg
Last known deal
May 2021
Website
droiaventures.com

Other firms investing in DeepTech

See all investors →

Is Droia Ventures the right fit for your deck?

Drop your pitch. AI scores it on the 8 dimensions VCs read for and ranks the 47,000+ active investors in the database by fit. Droia Ventures is one of them — and we'll tell you exactly where they sit in your top 100.